03 November 2003
The ‘no-reflow’ phenomenon in cerebral circulation
Isaac Julius Asiedu-Gyekye, Akadii VaktorovichMed Sci Monit 2003; 9(11): BR394-397 :: ID: 13278
Abstract
Background:The purpose of our research was to study the pattern of post-ischemic cerebral hemodynamic changes and observe the impact of enalapril on the course of these changes in cats.Material/Methods:The experiments were carried out on anesthetized cats using the autohemoperfusion method in cerebral and peripheral vessels with a stable volume of blood. Transitional peripheral (lower limb) and brain ischemia was simulated by stopping the autohemoperfusion pump for 15 minutes, tying various anastomoses in the neck region, and reducing arterial blood pressure (ABP) to 40–30 mm Hg, followed by reinfusion of the shed blood.Results:Intravenous administration of enalapril solution in a dosage of 0.25 mg·kg–1 in the early phase of reperfusion (10 minutes into the postischaemic period) prevented the development of long-term ‘no-reflow’ of cerebral blood flow, as observed in the controls. There was a 40.8±3.2% reduction of cerebrovascular tone, 39.3±3.1% in peripheral vessels, and 44.7±1.5% lower arterial blood pressure at the end of 120 minutes.Conclusions:Enalapril caused a reduction of cerebrovascular tone, completely eliminating the ‘no-reflow’ syndrome after brain ischemia and somewhat potentiated the hyperperfusion phase. At the same time, the drug did not aggravate the general hypotension observed after ischemia in the controls.
Keywords: Arteriovenous Anastomosis, Brain Ischemia, Cats, Cerebrovascular Circulation, Enalapril - pharmacology, Extremities - pathology, Ischemia
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952